Kornimate/medical-research-clean huggingface dataset:
evaluation of safety & efficacy of synbiotic on the incidence and recurrence of spontaneous bacterial peritonitis (sbp) in cirrhotics

Conditions: Cirrhosis With Ascites

Summary: background: spontaneous bacterial peritonitis (sbp) is a serious complication in patients of cirrhosis with ascites and may occur despite antibiotic prophylaxis. small bowel dysmotility and bacterial overgrowth have been documented to be related to sbp. aims: to investigate whether addition of prebiotic plus probiotics (synbiotics) to norfloxacin enhances the efficacy of norfloxacin in prevention of sbp in high risk patients with ascites. methods: a prospective, double blind, randomized controlled trial was conducted in consecutive high-risk cirrhotic patients with ascites who had either recovered from an episode of sbp (secondary prophylaxis) or who never had sbp but were at high risk for development of sbp (low ascitic fluid protein or serum bilirubin ≥2.5 mg/dl; primary prophylaxis). norfloxacin 400 mg once daily with synbiotic capsules (streptococcus faecalis jpc 30 million, clostridium butyricum 2 million, bacillus mesentericus jpc 1 million, lactobacillus sporogenes 50 million spores) 2 t.i.d. (group i) or norfloxacin 400 mg once daily with placebo (group ii) was given and occurrence of sbp within a period of 6 months (primary endpoint) or side-effects of therapy and mortality (secondary endpoints) were recorded. every patient received iv albumin to maintain a serum albumin level of \>3.2 g/dl. sbp was treated with intravenous antibiotics with albumin.


Eligibility criteria:
inclusion criteria: * cirrhosis with ascites with any one of following: * history of at least one episode of sbp, or * ascitic fluid protein less than or equal to 1g/dl, or * serum bilirubin more than or equal to 2.5 mg/dl exclusion criteria: * renal failure * hcc * hepatic encephalopathy * no consent
the effect of obesity on ventilation tube insertion

Conditions: Otitis Media; Obesity

Summary: obesity is associated with increased risk of surgical complications. ventilation tube insertion is one of the most frequent surgical procedures performed on children. however, the impact of obesity on surgical results or surgical related complication following ventilation tube insertion remains poorly understood. the aim of this study was to investigate the effect of obesity on the surgical results of ventilation tube insertion for otitis media with effusion (ome) in pediatric patients.

ome was diagnosed by the presence of fluid in the middle ear on otoscopy or tympanometry according to clinical practice guidelines . the diagnostic findings of pneumatic otoscopy and otomicroscopy include the tympanic membrane dullness, impaired mobility, and an air-fluid level or bubble. in addition, the type b or c tympanogram was considered positive for ome. indication for ventilation tub insertion includes history of ome lasting 3 months or longer, structural damage to tympanic membrane or middle ear and risk for speech, language learning difficulties. adenoidectomy is also performed when adenoid hypertrophy is founded during preoperative assessment. body weight and height were measured before ventilation tube insertion at hospital. body mass index (bmi) was calculated using the formula weight/ height2 (kg/m2).

Eligibility criteria:
inclusion criteria: * children aged 2-15 years with a diagnosis of ome who underwent ventilation tube insertion exclusion criteria: * children with a previous history of ventilation tube insertion * use of ventilation tubes other than paparella type i * head and neck anomalies * chronic or systemic disease

Keywords: otitis media obesity ventilation tube
interest of branched chain amino acids associated with a respiratory rehabilitation program in patients broncho chronic obstructive pulmonary disease

Conditions: Broncho Chronic Obstructive Pulmonary Disease

Summary: respiratory rehabilitation is one of the main treatments for copd in the early stages of the disease (stage 2 of gold) with a recognized effect on improving the capacity of the patients to exert effort by fighting against deconditioning. the effort. this treatment also improves the quality of life of patients and reduces the risk of respiratory exacerbations. the patients are very often malnourished and various studies have proposed the addition of oral supplementation such as hormone therapy (testosterone) to improve the exercise performance of these atrophied muscles. the use of branched-chain amino acids (aars) such as valine, leucine, isoleucine in this indication can be fully justified because they stimulate protein synthesis and promote muscle maintenance and repair.


Eligibility criteria:
inclusion criteria: * patients broncho chronic obstructive pulmonary disease in stages 2 and 3 of the gold classification, whose maximum expiratory volume on the first second is between 30% and 80% of the expected theoretical value, associated with a maximal expiratory volume ratio on the first second / vital capacity less than or equal to 70% of the expected theoretical value. * patients of both sexes, aged 40 to 80 years * in case of active smoking, patients must commit to interrupting it during the respiratory rehabilitation program that will be proposed to them in this study exclusion criteria: * - age \ 80 years * patients with a contraindication to exercise, * phenylketonuria * patients treated with long-term oxygen therapy and / or home ventilation will not be included. * patients with acute respiratory decompensation in the three months prior to inclusion. * patients with known allergy to milk, gluten, soy, egg and nuts * patients taking part in another clinical trial or who have participated in a clinical trial in the 3 months preceding this study.
impact of antioxidant micronutrients on intensive care unit (icu) outcome

Conditions: Critically Ill Patients; Cardiac Surgery; Trauma; Subarachnoid Hemorrhage

Summary: critically ill patients are generally exposed to an increased oxidative stress, which is proportional to the severity of their condition. endogenous antioxidant (aox) defenses are depleted particularly in those patients with intense inflammatory response. the hypothesis tested is that early i:v: administration of a combination of aox micronutrient supplements (se, zn, vit c, vit e, vit b1) would improve clinical outcome in selected critically ill patients, by reinforcing the endogenous aox defenses and reducing organ failure.

prospective randomized, double-blind, placebo-controlled, single-center trial. patients admitted to icu after complicated cardiac surgery, major trauma with or without brain injury, subarachnoid hemorrhage, and predicted by the clinicians to require \>48 hours of icu treatment. supplements: provided iv for 5 days

Eligibility criteria:
inclusion criteria: * adult patients admitted for above diagnosis assessed on admission by the medical team likely to require more than 48 hours of icu exclusion criteria: * absence of consent, participation in another study, liver cirrhosis or major burns and life expectancy \< 24 hours or a lack of commitment to full aggressive care (anticipated withholding or withdrawing treatments in the 48 hours

Keywords: selenium oxidative stress glutathione peroxidase critically ill outcome supplementation
vitamin c in atrial fibrillation ablation

Conditions: Atrial Fibrillation Ablation

Summary: single-center, double-blinded, randomized, controlled safety and feasibility pilot study of high dose iv ascorbic acid (200mg/kg) over 24 hours, divided into four doses and administered every six hours with a 30 minute iv infusion time per dose, compared to matched placebo infusion


Eligibility criteria:
inclusion criteria: 1. age \>/= 21 years 2. diagnosis of atrial fibrillation with plans for a catheter-based ablation procedure 3. ability to provide informed consent and willingness to be included in the study exclusion criteria: 1. known allergy to vitamin c 2. inability to obtain informed consent 3. diabetes mellitus either requiring the use of insulin therapy or not requiring the use of insulin therapy but which is uncontrolled, defined as a glycosylated hemoglobin of greater than or equal to 8% 4. prior catheter-based ablation for atrial fibrillation 5. pregnancy or breast feeding 6. active renal calculus 7. active acute or chronic infection (including hiv or hepatitis c) 8. active or recent (within 5 years) malignancy 9. autoimmune or autoinflammatory disease 10. recent or active use of immunosuppressive medications 11. non-english speaking 12. ward of the state (inmate, other)
a clinical study on lm103 for the treatment of advanced solid tumors

Conditions: Solid Tumor

Summary: this study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte lm103 injection in advanced solid tumor patients . the research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (tils) infusion, and il-2 therapy.


Eligibility criteria:
inclusion criteria: 1. the expected survival time is not less than 3 months. 2. clinical performance status of eastern cooperative oncology group (ecog) 0-1. 3. patients with advanced solid tumors confirmed by histology or cytology: advanced melanoma, cervical cancer/ovarian cancer, head and neck squamous cell cancer, non-small cell lung cancer, esophageal cancer and other solid tumors that have failed standard treatment regimens, cannot tolerate standard treatment, refuse or do not have standard treatment regimens available. 4. the patient has lesions that can be used for surgical resection (\>1.5 cm3) or biopsy puncture (no less than 6 lesions) for tils collection. 5. at least one measurable lesion as the target lesion after collecting tumor tissue from the patient (recist v1.1 criteria). 6. laboratory tests results during the screening period indicate that the subjects have sufficient organ function. exclusion criteria: 1. have a medical history of other malignant tumors other than the disease under study in the past 5 years, except for malignant tumors that can be expected to recover after treatment (including but not limited to thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer or ductal carcinoma in situ of the breast treated by radical surgery). 2. lm103 received systematic sex therapy of antineoplastic drugs (including chemotherapy, small molecule targeted drug therapy, hormone replacement therapy, etc.), or local antineoplastic therapy (such as radiotherapy, palliative radiotherapy for bone metastases\>2 weeks before the start of the study and intracranial stereotactic radiotherapy or resection of a single brain metastasis\>3 weeks before the start of the study were acceptable) within 4 weeks before lm103 infusion; or received clinical investigational drugs or equipment treatment. 3. adverse reactions caused by previous treatment have not recovered to ctcae (version 5.0) level 1 or below (excluding hair loss and neurotoxicity, which have been determined by the researchers to be irreparable and level 2 hypothyroidism for a long time). 4. previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
combined effects of inspiratory muscles training with pilate training in asthma patients

Conditions: Asthma

Summary: asthma is a chronic (long-term) condition that affects the airways in the lungs. the airways are tubes that carry air in and out of your lungs. in asthma the airways can become inflamed and narrowed at times. this makes it harder for air to flow out of your airways when you breathe out. when symptoms get worse, it is called an asthma attack. there is no permeant cure for asthma, but medical treatment and physiotherapy treatment can help to manage it. there is many physiotherapy protocols can be used for asthma patients like aerobic exercises, breathing exercise etc. the objective of our study is determine the combine effects of inspiratory muscle training with pilate training on dyspnea, cardiorespiratory fitness and quality of life in asthma patients. the randomized control trial will used as study design as study design for this this purpose simple random sampling technique will be used to allocate the sample in two group the sample size will be calculated by the g-power analysis. this study will conduct in jinnah hospital, lahore group a will receive both inspiratory training and pilate training and group b receive only inspiratory training, incentive spirometer the participants were instructed to hold the breath for 2-3 seconds then exhale slowly. this process was repeated 10 times or about 10-15minutes with rest in between 30 seconds. base line treatment is diaphragmatic breathing exercise .the session will repeated three times per week for 6 weeks with 40-minute sessions in pilates we include 5 pilate exercise, the hundred (rhythmic breathing), single leg stretch (rhythmic breathing), side kick, toe taps (set breathing pattern) ,leg pull front. pre and post measurement will be done using juniper asthma quality of life, 6 mint walk test, borges dyspnea scale and fatigue severity scale to measure the outcomes. data will be analyzed spss version 25. t-test and regression analysis will be used. key words: asthma patient, cardiorespiratory fitness, dyspnea, quality of life, pilate training, inspiratory muscle training

to determine the combined effects of inspiratory muscles training with pilate training on dyspnea, cardiorespiratory fitness quality of life in asthma patients

Eligibility criteria:
inclusion criteria: * age range from 30 to 50 (15) * both male and female * fev1 value range from 64% to less than 50% * medically cleared for cardiac rehabilitation. * medical treatment, for at least 6 months * clinically stable (i.e., no exacerbation or medication changes for at least 30 days. exclusion criteria * status asthmatics * patient with cardiac disease * age range from 30 to 50 (15) * both male and female * fev1 value range from 64% to less than 50% * medically cleared for cardiac rehabilitation. * medical treatment, for at least 6 months * clinically stable (i.e., no exacerbation or medication changes for at least 30 days.

Keywords: asthma patient, cardiorespiratory fitness, dyspnea, quality of life, pilate training, inspiratory muscle training
pilot study evaluating the toray satake balloon thermal ablation system for treatment of paroxysmal atrial fibrillation

Conditions: Paroxysmal Atrial Fibrillation

Summary: the purpose of this study is to collect preliminary safety and effectiveness data evaluating the toray satake balloon thermal ablation system (tsb)to treat subjects with symptomatic paroxysmal atrial fibrillation that is resistant to antiarrhythmic drug therapy.


Eligibility criteria:
inclusion criteria: * diagnosis of recurrent symptomatic paroxysmal atrial fibrillation * ≥2 symptomatic atrial fibrillation episodes * at least 1 paroxysmal atrial fibrillation episode documented by an ecg or device recording system in the 6 months prior to enrollment and * at least 1 additional (for a total of ≥2) paroxysmal atrial fibrillation episode documented by an ecg or device recording system, or, at a minimum, a physician's note indicating recurrent symptomatic atrial fibrillation * no episode \>7 days * failed to respond to or is intolerant of ≥1 class i, ii, iii or iv antiarrhythmic drug * able and willing to provide informed consent and health insurance privacy and portability act (hipaa) authorization * able and willing to meet all study requirements, including attending all post-ablation procedure assessments and visits exclusion criteria: * left atrium ≥50 mm * chronically used amiodarone in the 3 months prior to enrollment * previous left atrial ablation or surgical treatment for atrial fibrillation * left ventricular ejection fraction (lvef) \<35 % * new york heart association (nyha) class iii or iv heart failure * history of myocardial infarction (mi) or unstable angina in the 6 months prior to enrollment * multiple other exclusion criteria to establish overall good health and likely study compliance

Keywords: paroxysmal atrial fibrillation catheter ablation ablation techniques
objective assessment of disparity vergence after treatment of symptomatic ci in children

Conditions: Convergence Insufficiency

Summary: this study is designed to evaluate changes in objective measures of disparity vergence after office-based vergence/accommodative therapy (obvat) for convergence insufficiency (ci) in children 12-17 years old.

30 participants with normal binocular vision and 30 with ci will be recruited for this prospective study. all participants with ci will be treated with 12 weeks of office-based vergence/accommodative therapy. the primary outcome measure will be the average peak velocity for 4° symmetrical convergence steps. other objective outcome measures of disparity vergence will be time to peak velocity, latency, and accuracy. changes in clinical measures \[near point of convergence (npc), positive fusional vergence at near (pfv)\] and symptoms will be evaluated.

Eligibility criteria:
inclusion criteria: * ci symptom survey score ≥ 16 * exophoria at near at least 4 greater than at far * receded near point of convergence (npc) of 6 cm break * insufficient positive fusional vergence (pfv) at near (i.e., failing sheard's criterion or pfv ≤15 base-out break) * best-corrected distance visual acuity of 20/25 or better in each eye * random dot stereopsis appreciation of 500 seconds of arc or better * wearing appropriate refractive correction (spectacles of contact lenses) for at least 2 weeks prior to final determination of eligibility for any of the following uncorrected refractive errors (based on cycloplegic refraction within prior 12 months) * no use of bi prism or plus add at near for 2 weeks prior to study and for duration of study exclusion criteria: * constant strabismus at distance or near * esophoria of ≥ 2∆ at distance * vertical heterophoria ≥ 2∆ at distance or near * ≥ 2 line interocular difference in best-corrected visual acuity * near point of accommodation \>20 cm in either eye as measured by push-up method * manifest or latent nystagmus * history of strabismus surgery or refractive surgery * ci associated with head trauma or known disease of the brain * diseases known to affect accommodation, vergence, or ocular motility * inability to comprehend and/or perform any study-related test
evaluation of splinting in tetraplegia

Conditions: Spinal Cord Injury Cervical; Splints

Summary: this study compared pre-fabricated and custom resting hand splints among people who were in inpatient rehabilitation after a cervical spinal cord injury.

this was randomized parallel group controlled clinical trial where arms, not patients were the unit of randomization. this trial was funded by the craig h. neilsen allied health professional development award of the american spinal injury association (asia). this research was conducted at a 32-bed spinal cord injury and multi-trauma rehabilitation unit in an urban center. participants were recruited from an inpatient spinal cord injury rehabilitation unit. eligible participants were 18 years or older and undergoing acute rehabilitation after a cervical spinal cord injury with hand function impairment, and the primary occupational therapist deemed splinting intervention was required. each eligible extremity was randomized to receive a custom or pre-fabricated resting hand splint for night use.

Eligibility criteria:
inclusion criteria: * spinal cord injury * inpatient rehabilitation * limited hand function exclusion criteria: * under 18 * full hand function * orthopedic injury to hand
oxidant-antioxidant activity, free radicle activity, immune response and biomarkers in extracorporeal membrane oxygenation (ecmo) patients

Conditions: Cardiogenic Shock; Acute Myocardial Infarction; Myocarditis; Cardiomyopathy

Summary: we would like to investigate novel diagnostic methods or biomarkers to early predict the success of ecmo therapy for cardiogenic shock patients during the early stage after ecmo treatment.

in the investigators previous study (ann thorac surg 2002, 73: 538-545), the investigators knew that for those adult patients receiving ecmo support for post-cardiotomy cardiogenic shock, 1/3 of them would survive to discharge, 1/3 could not be weaned from ecmo and died on the ecmo support, and 1/3 could be weaned from ecmo support, but finally died of multiple organ failure. however, by clinical observation in the first few days of ecmo support, it would be very difficult to predict the outcome of a specified individual patient. therefore, the investigators usually wait for four to six days to know whether the ecmo treatment is successful or not. if the investigators could predict the result one or two days earlier, this would give physicians enough time to make medical decision. therefore, the early parameters that could be used to predict the outcome of ecmo treatment would be very valuable. the investigators also found that despite obscure clinical presentation, there was a significant difference in serum cytokines' concentration on the 3rd day of ecmo support between "ecmo successful" and "ecmo failure" patients. in this study, the investigators will further investigate leukocyte free radical activity, oxidation damage marker (8-ohdg concentration) in serum, whole blood glutathione peroxidase activity for antioxidation, serum il-6, il-12, il-8, il-10, transforming growth factor-β and other biochemical concentrations and immune cellular changes during the period of ecmo treatment. patient's blood samples before and 2, 6, 12, 24, 48, 72 hours after ecmo support treatment, at ecmo removal and icu discharge will be collected and used for the study. the measured factors and the final outcome will be compared. the investigators hope to find early factors change during ecmo treatment among biochemical, immunological and clinical parameters.

Eligibility criteria:
inclusion criteria: * 1. ≧ 18 yr. 2. cardiogenic shock, needing ecmo support exclusion criteria: * 1. pre-existing sepsis 2. pre-existing chronic renal failure (dialysis dependent), liver failure, multiple organ failure

Keywords: ecmo cardiogenic shock ros gpx cytokines